Current Clinical Issues Impacting the Lives of Patients Living With HIV/AIDS

Journal of the Association of Nurses in AIDS Care

Volumn 18, Issue 1 SUPPL., 2007, Pages

  Gallagher, Donna M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; CHEMICALLY INDUCED DISORDER; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; PATHOPHYSIOLOGY; RISK FACTOR;

ANTI-HIV AGENTS; DISEASE PROGRESSION; HIV INFECTIONS; HUMANS; LIPODYSTROPHY; RISK FACTORS;

EID: 33846591429     PISSN: 10553290     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jana.2006.11.011     Document Type: Article

References (19)

1. Amorosa V., Synnestvedt M., Gross R., Friedman H., MacGregor R.R., Gudonis D., et al. A tale of 2 epidemics: The intersection between obesity and HIV infection in Philadelphia. Journal of Acquired Immune Deficiency Syndromes 39 (2005) 557-561
2. Brown T.T., Cole S.R., Li X., Kingsley L.A., Palella F.J., Riddler S.A., et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Archives of Internal Medicine 165 (2005) 1179-1184
3. Danoff A., Shi Q., Justman J., Mulligan K., Hessol N., Robinson E., et al. Oral glucose tolerance and insulin sensitivity are unaffected by HIV infection or antiretroviral therapy in overweight women. Journal of Acquired Immune Deficiency Syndromes 39 (2005) 55-62
4. Department of Health and Human Services. (2006). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Retrieved May 5, 2006, from http://www.aidsinfo.nih.gov/guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&Search=Off&GuidelineID=7&ClassID=1
5. El-Sadr W.M., Mullin C.M., Carr A., Gilbert C., Rappoport C., Visnegarwala F., et al. Effects of HIV disease on lipid, glucose and insulin levels: Results from a large antiretroviral-naive cohort. HIV Medicine 6 (2005) 114-121
6. Fichtenbaum C.J., Gerber J.G., Rosenkranz S.L., Segal Y., Aberg J.A., Blaschke T., et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 16 (2002) 569-577
7. Grinspoon S. Insulin resistance in the HIV-lipodystrophy syndrome. Trends in Endocrinology and Metabolism 12 (2001) 413-419
8. Jerico C., Knobel H., Montero M., Ordonez-Llanos J., Guelar A., Gimeno J.L., et al. Metabolic syndrome among HIV-infected patients: Prevalence, characteristics, and related factors. Diabetes Care 28 (2005) 132-137
9. Johnson M., Grinsztejn B., Rodriguez C., Coco J., DeJesus E., Lazzarin A., et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 19 (2005) 153-162
10. Lichtenstein K.A. Redefining lipodystrophy syndrome: Risks and impact on clinical decision making. Journal of Acquired Immune Deficiency Syndromes 39 (2005) 395-400
11. Mallal S.A., John M., Moore C.B., James I.R., and McKinnon E.J. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 14 (2000) 1309-1316
12. Mallon P.W., Cooper D.A., and Carr A. HIV-associated lipodystrophy. HIV Medicine 2 (2001) 166-173
13. Murphy R.L., Sanne I., Cahn P., Phanuphak P., Percival L., Kelleher T., et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS 17 (2003) 2603-2614
14. National Institute of Diabetes and Digestive and Kidney Diseases. (2005). National diabetes statistics. Retrieved April 24, 2005, from http://diabetes.niddk.nih.gov/dm/pubs/statistics/#9
15. Purnell J.Q., Zambon A., Knopp R.H., Pizzuti D.J., Achari R., Leonard J.M., et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 14 (2000) 51-57
16. Riddler S.A., Smit E., Cole S.R., Li R., Chmiel J.S., Dobs A., et al. Impact of HIV infection and HAART on serum lipids in men. Journal of the American Medical Association 289 (2003) 2978-2982
17. Shikuma C.M., Day L.J., and Gerschenson M. Insulin resistance in the HIV-infected population: The potential role of mitochondrial dysfunction. Current Drug Targets. Infectious Disorders 5 (2005) 255-262
18. Tierney A., Grunfeld C., Kotler D.P., Shigenaga J.K., Doerrler W., Wang J., et al. Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. American Journal of Medicine 90 (1991) 154-162
19. Umeh O.C., and Currier J.S. Lipids, metabolic syndrome, and risk factors for future cardiovascular disease among HIV-infected patients. Current HIV/AIDS Reports 2 (2005) 132-139